Lupin Launches Zileuton Extended-Release Tablets

Pharma major Lupin Limited (Lupin) announced the launch of Zileuton Extended-Release Tablets, 600 mg, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier. The product would be manufactured at Lupin's Nagpur facility, India.

Zileuton Extended-Release Tablets, 600 mg, is the generic equivalent of Zyflo CR® Extended-Release Tablets, 600 mg, of Chiesi USA, Inc. and is indicated for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older.

Zileuton Extended-Release Tablets (RLD: Zyflo CR®) had an annual sales of approximately USD 40 million in the U.S. (IQVIA MAT June 2020).

Shares of LUPIN LTD. was last trading in BSE at Rs.957.95 as compared to the previous close of Rs. 957.85. The total number of shares traded during the day was 157896 in over 5872 trades.

The stock hit an intraday high of Rs. 969.05 and intraday low of 945.5. The net turnover during the day was Rs. 150999368.

Source : Equity Bulls

Keywords